Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
3.96
% (dilution ratio relative to total shares issued)Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of paid stock options (Series 16 stock acquisition rights)
Who receives how much
1,000,000 ordinary shares (10,000 Stock Acquisition Rights, 100 shares per right)
5 directors of the Company580,000 shares (5,800 Stock Acquisition Rights)
3 executive officers of the Company320,000 shares (3,200 Stock Acquisition Rights)
1 director of a subsidiary of the Company100,000 shares (1,000 Stock Acquisition Rights)
The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.
¥100 per Stock Acquisition Right
Total issue value
¥1,000,000
Amount of funds to be raised
Total amount paid: ¥1,000,000; estimated net proceeds: Not disclosed
発行済株式総数
3.96％
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
The closing price on the allotment date multiplied by 112%. Adjustment provisions apply in the event of a stock split, reverse stock split or certain issuances of new shares. Floor: Not disclosed.
Exercise period
From 1 May 2026 to 30 April 2031
Number of Stock Acquisition Rights
Total issued: 10,000 Stock Acquisition Rights; unexercised balance: Not disclosed
Reason for acquisition without consideration
The Company may acquire the Stock Acquisition Rights without consideration if approval or other authorization is obtained at a shareholders meeting for a corporate reorganization such as a merger, or if a holder of Stock Acquisition Rights no longer satisfies the exercise conditions.
Categories and Number of Persons Covered
5 directors of the Company: 5,800 Stock Acquisition Rights (580,000 shares), 3 executive officers of the Company: 3,200 Stock Acquisition Rights (320,000 shares), 1 director of a subsidiary of the Company: 1,000 Stock Acquisition Rights (100,000 shares)
Payment date
1 May 2026
Basis for determining the amount to be paid
The issue price of the Stock Acquisition Rights was set at ¥100 based on the fair value calculated by an independent valuation institution using a Monte Carlo simulation. The exercise price is the closing price of the Company's ordinary shares on the Growth Market of the Tokyo Stock Exchange on the allotment date multiplied by 112%. The share price assumption used for the valuation was ¥108, and the exercise price was ¥121.
Procedures under the Corporate Code of Conduct
Because the Stock Acquisition Rights are issued for consideration at fair value and on terms that are not particularly favorable, the issuance will be carried out without obtaining shareholder approval. In the deliberations on the individual allotments to the directors, the eligible directors, as specially interested parties, did not participate in the deliberations or resolutions.
Most recent equity financing
6th Series Stock Acquisition Rights, 9th Stock Acquisition Rights, 14th Series Stock Acquisition Rights, 8th Series Stock Acquisition Rights (granted to employees without consideration)
Impact on Business Performance
Impact of the issuance of these Stock Acquisition Rights on the Company's results: Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of paid stock options (Series 16 stock acquisition rights) |
| Number of shares to be issued or disposed of | 1,000,000 ordinary shares (10,000 Stock Acquisition Rights, 100 shares per right) |
| Issue price and disposal price | ¥100 per Stock Acquisition Right |
| Total issue value | ¥1,000,000 |
| Amount of funds to be raised | Total amount paid: ¥1,000,000; estimated net proceeds: Not disclosed |
| Payment date | 1 May 2026 |
| Intended allottee | Name 5 directors of the Company / Number of Shares 580,000 shares (5,800 Stock Acquisition Rights), Name 3 executive officers of the Company / Number of Shares 320,000 shares (3,200 Stock Acquisition Rights), Name 1 director of a subsidiary of the Company / Number of Shares 100,000 shares (1,000 Stock Acquisition Rights) |
| Dilution Rate | 3.96％ |
| Total number of issued shares | 25,243,500 shares → Not disclosed |
| Basis for determining the amount to be paid | The issue price of the Stock Acquisition Rights was set at ¥100 based on the fair value calculated by an independent valuation institution using a Monte Carlo simulation. The exercise price is the closing price of the Company's ordinary shares on the Growth Market of the Tokyo Stock Exchange on the allotment date multiplied by 112%. The share price assumption used for the valuation was ¥108, and the exercise price was ¥121. |
| Exercise price | The closing price on the allotment date multiplied by 112%. Adjustment provisions apply in the event of a stock split, reverse stock split or certain issuances of new shares. Floor: Not disclosed. |
| Exercise period | From 1 May 2026 to 30 April 2031 |
| Number of Stock Acquisition Rights | Total issued: 10,000 Stock Acquisition Rights; unexercised balance: Not disclosed |
| Reason for acquisition without consideration | The Company may acquire the Stock Acquisition Rights without consideration if approval or other authorization is obtained at a shareholders meeting for a corporate reorganization such as a merger, or if a holder of Stock Acquisition Rights no longer satisfies the exercise conditions. |
| Categories and Number of Persons Covered | 5 directors of the Company: 5,800 Stock Acquisition Rights (580,000 shares), 3 executive officers of the Company: 3,200 Stock Acquisition Rights (320,000 shares), 1 director of a subsidiary of the Company: 1,000 Stock Acquisition Rights (100,000 shares) |
| Procedures under the Corporate Code of Conduct | Because the Stock Acquisition Rights are issued for consideration at fair value and on terms that are not particularly favorable, the issuance will be carried out without obtaining shareholder approval. In the deliberations on the individual allotments to the directors, the eligible directors, as specially interested parties, did not participate in the deliberations or resolutions. |
| Most recent equity financing | 6th Series Stock Acquisition Rights, 9th Stock Acquisition Rights, 14th Series Stock Acquisition Rights, 8th Series Stock Acquisition Rights (granted to employees without consideration) |
| Impact on Business Performance | Impact of the issuance of these Stock Acquisition Rights on the Company's results: Not disclosed |
Items this document does not state (10)
Estimated issuance expensesSpecific use of fundsIntended allottee's holding policyTransfer restriction periodConditions for lifting transfer restrictionsTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to enhance corporate value over the medium to long term, increase the motivation and morale of the eligible individuals, and strengthen their commitment to sustainable earnings growth and securing profits. In addition, by triggering an obligation to exercise if the share price falls below 30% of the exercise price, the Company aims for management to bear the same economic risks as shareholders and to maintain a strong sense of responsibility for sustaining and enhancing corporate value.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.